A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study
A Single-blind, Placebo Controlled, Randomised Study to Evaluate Antiviral Activity and Safety and Pharmacokinetics of Inhaled PC786 Against Respiratory Syncytial Virus (RSV) in Healthy Adult Subjects in a Virus Challenge Model
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, E1 2AX
- hVIVO Services Ltd
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is in good health as determined by the Investigator based on medical history, physical examination, and routine laboratory tests at a screening evaluation.
- Male or female, aged between 18 and 55 years inclusive
- Body weight ≥ 50 kg and Body Mass Index (BMI) ≥ 18 kg/m2 and ≤ 30kg/m2
- Subject must provide written informed consent
- Serosuitable to the challenge virus.
Exclusion Criteria:
- History or evidence of any clinically significant or currently active major clinical illness.
- Any significant abnormality altering the anatomy of the nose or nasopharynx
- Any nasal or sinus surgery within six months of the study
- Abnormal lung function
- Positive human immunodeficiency virus (HIV), active hepatitis A (HAV), B (HBV), or C (HCV) test.
- Presence of cold like symptoms and/or fever on admission for the study
- History or currently active symptoms suggestive of upper or lower respiratory tract infection within 6 weeks of the study
- History of anaphylaxis-and/or a history of severe allergic reaction or significant intolerance to any food or drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PC786
Repeat dose
|
Repeat doses
|
|
Placebo Comparator: Placebo/vehicle
Repeat dose
|
Repeat doses
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
RSV viral load
Time Frame: Baseline to Day 28
|
AUC 0-t for RSV viral load measured in nasal washes by reverse transcription quantitative polymerase chain reaction (RT-qPCR)
|
Baseline to Day 28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants reporting one or more treatment-emergent adverse event (TEAE)
Time Frame: Screening to Day 28
|
Screening to Day 28
|
|
|
Number of participants who discontinue due to an adverse event
Time Frame: Screening to Day 28
|
Screening to Day 28
|
|
|
Number of participants who meet the markedly abnormal criteria for 12-lead ECG assessment at least once post dose
Time Frame: Screening to Day 28
|
Screening to Day 28
|
|
|
Number of participants who meet the markedly abnormal criteria for vital signs assessments at least once post dose
Time Frame: Screening to Day 28
|
Screening to Day 28
|
|
|
Number of participants who meet the markedly abnormal criteria for safety laboratory assessments at least once post dose
Time Frame: Screening to Day 28
|
Screening to Day 28
|
|
|
Number of participants who meet the markedly abnormal criteria for spirometry (FEV1 & FVC measured together) assessments at least once post dose
Time Frame: Screening to Day 28
|
Screening to Day 28
|
|
|
Area under the plasma concentration versus time curve (AUC) of PC786 measured in plasma
Time Frame: Pre-dose and at multiple time points to Day 12
|
Pre-dose and at multiple time points to Day 12
|
|
|
Maximum observed concentration (Cmax) of PC786 measured in plasma
Time Frame: Pre-dose and at multiple time points to Day 12
|
Pre-dose and at multiple time points to Day 12
|
|
|
Time maximum concentration observed (Tmax) of PC786 measured in plasma
Time Frame: Pre-dose and at multiple time points to Day 12
|
Pre-dose and at multiple time points to Day 12
|
|
|
Apparent terminal half life (T1/2) of PC786 measured in plasma
Time Frame: Pre-dose and at multiple time points to Day 12
|
Pre-dose and at multiple time points to Day 12
|
|
|
Determination of nasal concentrations of PC786
Time Frame: Pre-dose and at multiple time points to Day 28
|
PC786 concentrations in mucosal lining fluid collected using synthetic absorptive matrix
|
Pre-dose and at multiple time points to Day 28
|
|
Comparison of mucus production following treatment with PC786 or placebo post viral inoculation
Time Frame: Baseline to Day 12
|
Reduction in weight of mucus produced post viral infection
|
Baseline to Day 12
|
|
Comparison of the effect of treatment with PC786 or placebo on RSV symptoms
Time Frame: Baseline to Day 12
|
Composite score of self-reported symptoms on a symptom diary card.
Nasal symptoms, sneezing, sore throat, cough, headache, wheezing, chest tightness, shortness of breath, joint aches, feverishness, malaise, earache are assessed using a score of 0 (no symptoms), 1 (just noticeable), 2 (bothersome but able to participate in activities), 3 (bothersome and not able to participate in activities)
|
Baseline to Day 12
|
|
Change in viral load measured in nasal wash
Time Frame: Baseline to Day 12
|
Change in viral load before first dose of PC786 to Day 12
|
Baseline to Day 12
|
|
Time to non-detectability of virus measured in nasal wash
Time Frame: Baseline to Day 12
|
Baseline to Day 12
|
|
|
Peak viral load measured in nasal wash
Time Frame: Baseline to Day 12
|
Baseline to Day 12
|
|
|
Time peak viral load observed measured in nasal wash
Time Frame: Baseline to Day 12
|
Baseline to Day 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Bryan J Murray, MBBS, hVIVO Services Ltd
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PC_RSV_003
- 2017-002563-18 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.